Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Developmental disorder" patented technology

Developmental disorders comprise a group of psychiatric conditions originating in childhood that involve serious impairment in different areas. There are several ways of using this term. The most narrow concept is used in the category "Specific Disorders of Psychological Development" in the ICD-10. These disorders comprise developmental language disorder, learning disorders, motor disorders and autism spectrum disorders. In broader definitions ADHD is included, and the term used is neurodevelopmental disorders. Yet others include antisocial behavior and schizophrenia that begins in childhood and continues through life. However, these two latter conditions are not as stable as the other developmental disorders, and there is not the same evidence of a shared genetic liability.

Anti-IL-17 Antibodies

Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.
Owner:ELI LILLY & CO

Responsive therapy for psychiatric disorders

An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.
Owner:NEUROPACE

System and method for expressive language, developmental disorder, and emotion assessment

In one embodiment, a method for detecting autism in a natural language environment using a microphone, sound recorder, and a computer programmed with software for the specialized purpose of processing recordings captured by the microphone and sound recorder combination, the computer programmed to execute the method, includes segmenting an audio signal captured by the microphone and sound recorder combination using the computer programmed for the specialized purpose into a plurality recording segments. The method further includes determining which of the plurality of recording segments correspond to a key child. The method further includes determining which of the plurality of recording segments that correspond to the key child are classified as key child recordings. Additionally, the method includes extracting phone-based features of the key child recordings; comparing the phone-based features of the key child recordings to known phone-based features for children; and determining a likelihood of autism based on the comparing.
Owner:LENA FOUNDATION

System and method for expressive language, developmental disorder, and emotion assessment

In one embodiment, a method for detecting autism in a natural language environment using a microphone, sound recorder, and a computer programmed with software for the specialized purpose of processing recordings captured by the microphone and sound recorder combination, the computer programmed to execute the method, includes segmenting an audio signal captured by the microphone and sound recorder combination using the computer programmed for the specialized purpose into a plurality recording segments. The method further includes determining which of the plurality of recording segments correspond to a key child. The method further includes determining which of the plurality of recording segments that correspond to the key child are classified as key child recordings. Additionally, the method includes extracting phone-based features of the key child recordings; comparing the phone-based features of the key child recordings to known phone-based features for children; and determining a likelihood of autism based on the comparing.
Owner:LENA FOUNDATION

Bone Conduction Apparatus and Multi-sensory Brain Integration Method

The present disclosure provides a therapeutic method applicable to learning, attention, cognitive and developmental disorders. This method combines auditory, visual and vestibular stimuli into a systematic method which can be customized to address individual learning, attention and processing disorders. This method may be wirelessly implemented in a group setting. A device for providing vestibular and somatosensory stimulation through bone conduction of sound waves to skeletal bones is provided in the form of a pad that is applied to or wrapped around the individual in treatment, which is comfortable in use and may contain particulate filler material capable of providing bone conduction stimulation adjacent to the location of a bone conduction transducer and expand the sound conduction site over a larger area.
Owner:INTEGRATED LISTENING SYST

Screening, Diagnosis and Prognosis of Autism and Other Developmental Disorders

The invention provides a method and system combining functional genomic and genetic, proteomic, anatomic neuroimaging, functional neuroimaging, behavioral and clinical measurements and data analyses for autism pediatric population screening, diagnosis or prognosis. More specifically, the invention provides a weighted gene and feature test for autism which uses a weighted gene signature matrix for comparison to a reference database of healthy and afflicted individuals. The invention also provides normalized gene expression value signatures for comparison to a reference database. The invention additionally combines either the weighted gene or the normalized gene analysis with comparisons to a gene-networks signature matrix, a multi-modal signature matrix, and a collateral features signature matrix for improved accuracy in screening, diagnostic and prognostic relevance for autism, particularly for newborns, babies ages birth to 1 year, toddlers ages 1 to 2 years, toddlers ages 2 to 3 years and young children ages 3 through 4 years.
Owner:RGT UNIV OF CALIFORNIA

Composite assay for developmental disorders

This invention relates generally to diagnosing developmental disorders by detecting two or more genetic characteristics from a nucleic acid extracted from a sample taken from a patient. The genetic characteristics detected include nucleic acid expression profiles, nucleic acid sequences, and nucleic acid copy numbers. The genetic characteristics may be detected using sequencing technology, array based technology, or both. At least two genetic characteristics are compared to respective controls. From the comparison a diagnostic profile of a developmental disorder for the patient is formed.
Owner:LAB OF AMERICA HLDG

Computer aided diagnostic system incorporating 3D shape analysis of the brain for identifying developmental brain disorders

A computer aided diagnostic system and automated method classify a brain through modeling and analyzing the shape of a brain cortex, e.g., to detect a brain cortex that is indicative of a developmental disorder such as ADHD, autism or dyslexia. A model used in such analysis describes the shape of brain cortices in terms of spherical harmonics required to delineate a unit sphere corresponding to the brain cortex to a model of the brain cortex.
Owner:UNIV OF LOUISVILLE RES FOUND INC

Composition improving memory and preparation method thereof

The present invention provides a composition improving memory and a preparation method thereof. The composition mainly consists of the following components: a semen ziziphi spinosae extract, phosphatidylserine and DHA (docosahexenoic acid). The composition can greatly reduce the required amounts of phosphatidylserine and DHA to play the same functions, and has efficacies of preventing and curing brain developmental disorders of infants and pregnant women, adolescent mental deterioration, and premature senile cranial nerve degeneration.
Owner:AOLING BODA MEDICINE SCI & TECH DEV BEIJING

Method for detection treatment and prevention of neurological development disorders

A method for detection, treatment, and prevention of neurological development disorders utilizes an infrared imaging device, meridian theory of traditional Chinese medicine, and predetermined amounts of solid water particles to detect, treat, and prevent a neurological developmental disorder, such as autism. The method detects the disorder by initially identifying at least one hot spot on a patient with an infrared imaging device. At least one acupoint along a meridian pathway is identified. The hot spot is correlated with at least one acupoint located along the meridian pathway. The nexus of the hot spot and the meridian pathway indicates a potential neurological development disorder. A degree of irregularity of the internal organ is discerned by measuring a quantitative temperature at the nexus. A solid water particle is applied through a delivery means, such as oral, topical, vapor, and intravenous administration for treatment of the neurological developmental disorder.
Owner:AMERICAN QUANTUM HEALTH INC +1

Methods and systems for preparation of treatment plans

InactiveUS20120052468A1Electrical appliancesTeaching apparatusPersonalizationAcquiring skills
A program module is configured with sub-modules for child development assessment, presentation of progress charts and development of individualized treatment plans. An assessment sub-module includes assessment tools for behavioral educators of children with developmental disorders to identify mastered and non-mastered skills of a subject child. A treatment plan sub-module is configured to permit the behavioral educator to determine a set of lessons from a curriculum, which lessons define an individualized, Applied Behavior Analysis (ABA)-based program of instruction based on the needs of a subject child as identified by the assessment tools. A progress chart sub-module is configured to permit monitoring of the subject child's progress as the subject child progresses through the lessons of the individualized program under the guidance of one or more instructors.
Owner:CENT FOR AUTISM & RELATED DISORDERS LLC

Use of polymorphisms for identifying individuals at risk of developing autism

The present invention relates to nucleic-acid based diagnostics and the use of such diagnostics for the diagnosis of developmental disorders. Novel methods of assessing individuals for the risk of developing autism through the identification of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene alone or in combination with other genes associated with methylation pathways are identified. Methods of identifying those individuals that are at increased and / or decreased risk for developing autism are provided.
Owner:YASKO AMY

Use of polymorphisms for identifying individuals at risk of developing autism

InactiveUS20130317006A1Increased and decreased riskBiocideOrganic active ingredientsDevelopmental disorderCvd risk
The present invention relates to nucleic-acid based diagnostics and the use of such diagnostics for the diagnosis of developmental disorders. Novel methods of assessing individuals for the risk of developing autism through the identification of mutations of the CFTR gene alone or in combination with other genes associated with the methylation pathways are identified. Methods of identifying those individuals that are at increased and / or decreased risk for developing autism are provided.
Owner:YASKO AMY

Cyclopropanamine compound and use thereof

ActiveUS20150291577A1Superior LSD inhibitory actionHigh LSD selectivityBiocideNervous disorderNoonan syndromeNodular sclerosis
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formulawherein each symbol is as defined in the present specification, or a salt thereof.
Owner:TAKEDA PHARMA CO LTD

Prodrug of fluorine-containing amino acid

Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.
Owner:TAISHO PHARMACEUTICAL CO LTD

Application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases

The invention relates to application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases. The preservation number of the lactobacillus reuteri is CGMCC (China General Microbiological Culture Collection Center) No. 21577. The lactobacillus reuteri can improve the composition of intestinal flora of patients with developmental disorder diseases such as the Prallard-Willard syndrome and the autism, and improve the disorder of the intestinal flora. The bacteria can prevent obesity or promote weight loss caused by diet, can improve brain development of patients with developmental disorder diseases such as the Prallard-Willie syndrome and autism, can improve social contact disorders and communication disorders of the patients, and can improve fine exercise ability of the patients.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products